LY2228820

DRUG3 trials

Sponsors

Eli Lilly and Company, Centre Jean Perrin

Conditions

Adult GlioblastomaAdvanced CancerEpithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Phase 1

A Study of LY2228820 in Participants With Advanced Cancer

CompletedNCT01393990

Eli Lilly and CompanyAdvanced Cancer

Start: 2008-09-04End: 2013-12-14Updated: 2020-03-24

A Study LY2228820 for Recurrent Ovarian Cancer

CompletedNCT01663857

Eli Lilly and CompanyEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Start: 2012-07-31End: 2018-05-11Updated: 2019-09-11

Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma

CompletedNCT02364206

Centre Jean PerrinAdult Glioblastoma

Start: 2015-06-08End: 2019-08-31Updated: 2019-08-14

Related Papers

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.

2019-11-2953 citations

A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer.

Journal of Clinical Oncology2019-05-203 citations